Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)

NCT01439880 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01439880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01439880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
October 7, 2011
Completion date
June 20, 2018
Enrollment
1,324 (actual)
Sites
187

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia